Bleonko фл. 15ME No. 1

General characteristics. Structure:

Main physical and chemical properties: powder of white color; Structure: 1 bottle contains Bleomycinum - 15 ME.

Pharmacological properties:

Antineoplastic means. Drug is A2 fraction allocated from culture of Streptomyces verticillus, the containing antineoplastic antibiotic. The mechanism of action is connected with ability to cause fragmentation of molecules DNA. Has poorly expressed miyelodepresivna and immunodepressive activity. Slightly suppresses a hemopoiesis.

Pharmacokinetics. The elimination half-life at clearance of creatinine more than 35 ml/min. makes 115 min. Bleonko has property to collect (at parenteral administration) in skin thanks to what drug is especially effective at a carcinoma cutaneum and mucous membranes. It is removed by kidneys, 60 - 70% are preferential in not changed look.

Indications to use:

Carcinoma cutaneum, gullet cancer, lung cancer, cancer of a neck of uterus, penis cancer, glioma, cancer of a thyroid gland, malignant tumors of the head and neck (cancer of an upper jaw, language, lip, throat, throat, oral cavity, etc.); kidney cancer, lymphogranulomatosis, nekhodzhkinsky lymphoma, germinogenny tumors of a small egg and ovaries. Sarcomas of soft tissues, osteosarcoma. Drug is used for treatment and prevention of exudative pleurisy and treatment of exudative peritonitis at malignant tumors.

Route of administration and doses:

Doses appoint individually depending on indications, a condition of the patient. Bleonko is entered into a vein, into a muscle, under antineoplastic by therapies. In a vein enter 15 - 30 mg into 15 - 20 ml of isotonic solution of sodium of chloride or glucose. In a muscle or under skin of 15-30 mg in 5 ml of solvent. Enter 5-15 mg into an artery. To elderly people the dose is reduced - appoint 15 mg 2 times a week.

Bleonko is entered by 2 times a week. Frequency of introductions can be changed depending on degree of manifestation of symptoms; as much as possible - 1 time a day, it is minimum - once a week. The total course dose should not exceed 300 - 400 mg. For a maintenance therapy appoint 15 mg of Bleomycinum of about 10 times once a week. Repeated courses are conducted with an interval of 3-4 weeks. At Bleonko's introduction by the patient which received пепломицин to a total dose on a course of treatment the general dose of both drugs is. Solution preparations. Solution for injections is prepared just before use. For introduction to Bleonko's vein dissolve in 20 ml of isotonic solution of sodium of chloride, enter within 5 min. For introduction to a muscle dissolve in 5 ml of isotonic solution of sodium of chloride, at morbidity previously enter 1 - 2 ml of 1 - 2% of solution of novocaine.

Features of use:

By Bleonko appoint with care at the patients having diseases of lungs, the patient with renal failures, the patient with coronary heart disease with heart diseases, elderly, sick with chicken pox, to acute infectious diseases, and also to patients who receive radiation therapy.

At emergence of signs of pulmonary toxicity (cough, short wind, rattles in lungs) it is necessary to stop immediately drug use, to appoint GKS and antibiotics for the purpose of prevention of development of consecutive infection. During treatment it is necessary to control systematically function of a respiratory organs, X-ray inspection of lungs, to control function of kidneys, a liver.

Safety of use for children is not established.

Side effects:

Cough, intersticial pneumonia, fibrosis of pulmonary fabric, focal giperkeratoza, hyperpegmentation, dermatitis, deformation of nails, alopecia, angular stomatitis, allergic reactions (erythema, small tortoiseshell), temperature increase, nausea, vomiting, anorexia, headache, dizziness, abnormal liver function, kidneys, azoospermism, amenorrhea.

Repeated introduction to a vein can lead to consolidation of a vein, narrowing in an injection site, at introduction to a muscle - consolidation in an injection site, morbidity.

Interaction with other medicines:

At simultaneous use of Bleonko with anesthetics perhaps bystry deterioration in functions of lungs. At simultaneous use with the drugs causing myelotoxic and to a pnevmotoksichn of action the risk of development of side effect increases. At simultaneous use with Cisplatinum delay of clearance of Bleonko and increase in its toxic action even is possible at use in low doses owing to nephrotoxic action of Cisplatinum. Use of Vincristinum before Bleonko's appointment is stopped by a cellular cycle in a mitosis phase that leads to increase in sensitivity of cells of a tumor to Bleonko's action.

Contraindications:

The expressed breath dysfunctions, fibrosis of pulmonary fabric, the expressed renal failures (clearance of creatinine less than 25-35 ml/min.), a liver, a disease of cardiovascular system, the period of pregnancy and feeding by a breast, hypersensitivity to Bleomycinum and similar drugs (пепломицин).

Overdose:

Fervescence, nausea, vomiting, anorexia. Treatment - symptomatic and a maintenance therapy.

Storage conditions:

To store in the dry, protected from light place at a temperature from +2 °C to +8 °C.

Period of validity - 2 years.

Issue conditions:

According to the recipe

Packaging:

On 15 ME in a bottle, 1 bottle from glass in a cardboard box.